RVMD Key Statistics, Chart & Performance
The current stock price of RVMD is 120.28 USD. In the past month the price increased by 56.74%. In the past year, price increased by 198.54%.
RVMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 98.53% of all stocks.
RVMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVMD. RVMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RVMD Financial Highlights
Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.17. The EPS decreased by -44.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| Debt/Equity | 0.16 |
RVMD Forecast & Estimates
27 analysts have analysed RVMD and the average price target is 92.82 USD. This implies a price decrease of -22.83% is expected in the next year compared to the current price of 120.28.
For the next year, analysts expect an EPS growth of -59.96% and a revenue growth 1279.08% for RVMD
RVMD Ownership
RVMD Latest News, Press Relases and Analysis
RVMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.44B |
Related stock screener links
About RVMD
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063 US
CEO: Mark A. Goldsmith
Employees: 809
Phone: 16504816801
REVOLUTION MEDICINES INC / RVMD FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of RVMD stock?
The current stock price of RVMD is 120.28 USD. The price decreased by -2.43% in the last trading session.
Does REVOLUTION MEDICINES INC pay dividends?
RVMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVMD stock?
RVMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in REVOLUTION MEDICINES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RVMD.
Can you provide the market cap for REVOLUTION MEDICINES INC?
REVOLUTION MEDICINES INC (RVMD) has a market capitalization of 23.25B USD. This makes RVMD a Large Cap stock.
Can you provide the ownership details for RVMD stock?
You can find the ownership structure of REVOLUTION MEDICINES INC (RVMD) on the Ownership tab.